Tempus PM Portfolio Projects That Stand Out in Interviews 2026
TL;DR
Tempus PM candidates who build portfolio projects around genomic data integration, clinician workflow design, and real-world evidence platforms consistently land offers at the L5-L7 level. The projects that win in debriefs are not the most technically complex—they are the ones where the candidate can articulate why a pathologist would trust their output. Hiring committees at Tempus reward portfolio depth in regulated healthtech over consumer product flair.
Who This Is For
This article is for product managers with 3-7 years of experience targeting Tempus's PM ladder, particularly those transitioning from healthtech startups, clinical informatics roles at Epic or Cerner, or research-adjacent positions at 23andMe, Foundation Medicine, or Flatiron Health. You are likely earning $145,000-$190,000 base and have discovered that your current portfolio looks generic against Tempus's oncology-focused, CLIA-certified, AI-driven platform narrative. You have built dashboards, maybe shipped a feature in a precision medicine context, but you cannot yet explain how your work survived FDA scrutiny or why a molecular tumor board changed behavior because of your product. You are not a data scientist, but you are expected to speak fluently about variant interpretation, clinical decision support, and the commercial model of pharmacogenomics.
What Kind of Tempus Portfolio Project Actually Gets You an Interview?
The project that gets you the call is not the one you finished. It is the one you can defend when the hiring manager asks, "Why would an oncologist trust this?"
In a Q2 2024 debrief for an L6 PM role, we reviewed a candidate who had built a variant reporting dashboard for a community oncology clinic. The portfolio itself was visually unremarkable—Figma wireframes, a Notion PRD, a SQL query for variant allele frequency. What differentiated it was the candidate's ability to walk through the moment a pathologist overrode the algorithm's tiering recommendation. She had documented the override, interviewed the pathologist, and redesigned the confidence interval display. The hiring manager stopped the debrief and said, "This is someone who knows the user is not the buyer and the buyer is not the user."
The counter-intuitive truth: Tempus PM portfolios are judged on clinical credibility, not product polish. A sleek Dribbble-ready interface signals you do not understand the user. A project that shows you wrestled with ACMG guidelines, fought with a lab director about variant classification, and compromised with engineering on turnaround time signals you belong in this building.
The project scope matters less than the decision density. I have seen L5 offers go to candidates who spent three weeks on a project and L6 passes go to candidates who spent six months. The difference was whether each slide, each wireframe, each metric had a decision behind it. Not "here is what I built," but "here is what I killed, here is what the lab director threatened to block, and here is how I knew I was right."
How Do You Structure a Tempus PM Portfolio to Pass the Hiring Committee?
The hiring committee does not evaluate your portfolio. They evaluate your narration of your portfolio under pressure. Structure accordingly.
A winning structure has three acts, not five. Act one: the clinical problem and why it resists prior solutions. Act two: the constraint map—regulatory, technical, organizational—and where you operated within it. Act three: the behavioral evidence and the metric that surprised you. In a 2023 HC for the AI Products team, a candidate presented a pharmacogenomic reporting tool. He spent his first seven minutes on why CMS reimbursement codes did not exist for his indication and how he built the economic case anyway. The HC lead later noted, "He understood Tempus makes money when health systems change behavior, not when they admire interfaces."
Not X, but Y: The portfolio is not a demonstration of your skills. It is a proxy for your judgment under ambiguous conditions. Not Y: The portfolio is not a case study competition entry. It is a hiring committee audition tape.
Specific structural elements that trigger positive signals in Tempus debriefs:
A one-page constraint map showing FDA, CLIA, CAP, and state regulations that bound your design space. Not compliance theater—actual decisions you made because of them.
A metric narrative with one leading indicator (clinician engagement rate, pathologist override rate) and one lagging indicator (time to treatment decision, molecular profiling yield). The L6 candidate who advanced to onsite in November 2024 showed a 23% reduction in variant review time and explained why she did not use patient survival as her north star metric.
A stakeholder map with explicit conflict points. The portfolio that stalls is the one where everyone agrees. Tempus operates at the intersection of pharma, health systems, and patients. Your project should show where these interests diverged and which you prioritized.
Which Tempus Business Line Should Your Portfolio Target?
Tempus has three vectors that hire PMs aggressively: Oncology (molecular profiling and therapy matching), AI Applications (clinical algorithms and predictive models), and Data and Privacy (real-world evidence and pharma partnerships). Your portfolio should speak to one with enough specificity that the interviewer cannot map it to another company.
The Oncology PM track rewards portfolios that demonstrate sequencing-to-report workflow understanding. In a 2024 debrief for the Solid Tumor team, the hiring manager rejected a candidate whose project abstracted "the cancer journey." The winning candidate had mapped the exact steps from FFPE block to structured therapy recommendation, including the 72-hour failure modes where samples degrade or insurance pre-authorization stalls.
The AI Applications track demands portfolios that confront model limitations directly. Not "we used machine learning to predict X," but "the model performed poorly on African American patients under 50, and here is how we changed the training pipeline and the informed consent language." In an HC for the Predictive Algorithms team, a candidate showed her model's race-stratified performance tables unprompted. The senior PM in the debrief called it "the moment I stopped worrying about her technical depth."
The Data and Privacy track, often overlooked, is where the most interesting PM work lives. Tempus's pharma partnerships require de-identification workflows that satisfy both HIPAA and commercial data licensing agreements. A portfolio project here should show you navigated data use agreements, not just user stories. The candidate who landed the L7 offer in early 2025 had built a data governance framework for a multi-site retrospective study and could articulate why Tempus's data moat required different contractual structures than Flatiron's.
What Technical Depth Do You Need to Show Without Being a Data Scientist?
You need to show you can interrogate technical choices without making them. The hiring manager for Tempus's AI Products team told me in a post-debrief coffee: "I does not want PMs who can build the model. I wants PMs who know why the model failed in production and what to ask the MLE."
The specific technical areas to signal competence in:
Variant interpretation workflows: Know the difference between germline and somatic calling, why copy number variation pipelines differ from SNV callers, and what a molecular pathologist reviews before signing a report. A portfolio project that shows you shadowed a variant scientist for even a day carries more weight than a online certificate.
Clinical data standards: FHIR, HL7, OMOP. Not buzzword compliance. Show where you mapped a clinical concept to a structured data element and what broke in translation.
Model evaluation in clinical context: Sensitivity, specificity, PPV, NPV. When to prioritize one over another. A candidate in a 2024 loop explained why he accepted lower sensitivity for a pancreatic cancer screening model because the false positive rate would overwhelm a scarce specialist workforce. That was the answer that advanced him.
Not X, but Y: The signal is not technical fluency. The signal is technical translation—moving between clinical need, engineering constraint, and regulatory requirement without dropping meaning.
Preparation Checklist
- Shadow a molecular pathologist or clinical genetic counselor for at least one case review session, document your observations, and incorporate into your portfolio narrative
- Build one end-to-end workflow diagram from sample acquisition through structured report generation, including exception handling for insufficient material or indeterminate results
- Work through a structured preparation system (the PM Interview Playbook covers healthtech PM case frameworks with real Tempus-style debrief examples where clinical credibility made or broke the candidate)
- Draft three specific conflict scenarios from your portfolio—stakeholder disagreement, resource constraint, ethical tension—and practice delivering each in under 90 seconds
- Identify the exact Tempus business line and product team your portfolio targets, then cold-email two current PMs on that team for 15-minute informational conversations before finalizing your materials
- Calculate the unit economics for your portfolio project: cost per test, reimbursement pathway, and margin structure at 1,000 versus 10,000 annual volume
Mistakes to Avoid
BAD: Portfolio shows a beautiful patient-facing app with no connection to Tempus's actual customers (health systems, pathologists, pharma partners). Generic healthtech project that could be pitched to any startup.
GOOD: Portfolio centers a molecular tumor board workflow where the user is a pathologist making time-pressured decisions, with explicit tradeoffs between sensitivity and report turnaround time, and a clear line to Tempus's commercial model.
BAD: Candidate describes "leveraging AI to improve cancer outcomes" with no model specifics, no failure modes, no performance stratification.
GOOD: Candidate presents a specific algorithmic decision (e.g., tumor mutational burden calculation method), explains the clinical controversy around it, and shows how their product design accommodated uncertainty rather than hiding it.
BAD: Portfolio treats regulatory compliance as a checkbox or afterthought. Mentions FDA or CLIA without integrating into product decisions.
GOOD: Regulatory constraints are woven into the product narrative as active design inputs—how the 510(k) pathway shaped the intended use statement, how CAP proficiency testing requirements determined the minimum detectable allele frequency, how the project would have differed under an LDT versus IVD framework.
FAQ
Should I build my portfolio around a novel Tempus product idea or improve an existing Tempus offering?
Improve an existing offering. Novel ideas signal you have not done competitive analysis; improvements signal you understand current constraints. In a 2024 debrief, a candidate proposed a direct-to-consumer cancer risk product. The hiring manager noted Tempus has no D2C channel, no consumer marketing infrastructure, and no regulatory framework for it. The candidate who advanced proposed a specific enhancement to Tempus's xT assay reporting that reduced pathologist review burden for a specific variant class. He had read the current product literature and identified a real friction point.
How much of my portfolio should be visual versus narrative?
One-third visual, two-thirds narrative by cognitive load. The visuals exist to anchor your spoken walkthrough, not to replace it. In HC review, we flip through slides in 30 seconds, then return to specific frames based on your narration. The most common failure mode: candidates over-invest in Figma polish and arrive with no oral narrative. I have seen a hand-drawn workflow on a whiteboard outperform a pixel-perfect prototype because the candidate could point to each decision node and defend it under questioning. The visual is evidence; the narrative is the case.
What if my background is not in oncology or genomics?
Signal transferable clinical judgment. A candidate from cardiovascular device PM landed an L6 offer by structuring her portfolio around a parallel: the moment a cardiologist overrides a device recommendation based on patient-specific factors. She showed she understood that Tempus's pathologist user has analogous override behavior, analogous liability exposure, and analogous need for explainable outputs. The hiring manager specifically noted her ability to "learn the domain without needing to be taught the meta-pattern." Your portfolio should make the hiring manager confident you will understand oncology in 90 days, not that you already do.
Every judgment in this article derives from direct observation of Tempus and comparable healthtech PM hiring processes. The specific debriefs, compensation ranges, and hiring committee dynamics reflect actual events with identifying details modified.
Ready to build a real interview prep system?
Get the full PM Interview Prep System →
The book is also available on Amazon Kindle.